Patents by Inventor Patrick Baeuerle

Patrick Baeuerle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220298478
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 22, 2022
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Patent number: 11377638
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 5, 2022
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Patent number: 11352403
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20220160771
    Abstract: Some embodiments of the disclosure provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for FLT3, an antigen binding domain specific for a second antigen, a transmembrane domain, and an intracellular T cell signaling domain. Some embodiments of the disclosure provides bicistronic CARs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Application
    Filed: April 10, 2020
    Publication date: May 26, 2022
    Inventors: Iulia DIACONU, Cherylene PLEWA, Patrick BAEUERLE, Sandra MILASTA, Jed WILTZIUS
  • Publication number: 20220056096
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 24, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11242376
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: February 8, 2022
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Publication number: 20210403524
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11154617
    Abstract: Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: October 26, 2021
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo
  • Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Publication number: 20210238286
    Abstract: The invention relates to multi-specific binding proteins that bind CD19, CD3, and serum albumin. The invention also relates to pharmaceutical compositions comprising these multi-specific binding proteins, expression vectors and host cells for making these multi-specific binding proteins, and methods of use of these multi-specific binding proteins in treating hematologic cancers.
    Type: Application
    Filed: June 7, 2019
    Publication date: August 5, 2021
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta
  • Publication number: 20210206827
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 8, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Publication number: 20210187022
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 24, 2021
    Inventors: Daniel GETTS, Ekta PATEL, Patrick BAEUERLE, Robert HOFMEISTER
  • Publication number: 20210179735
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Patent number: 11028142
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: June 8, 2021
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Publication number: 20210100902
    Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Patent number: 10954311
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Publication number: 20210079057
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 13, 2018
    Publication date: March 18, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Patent number: 10849973
    Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • Patent number: 10844134
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 24, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto